INSPECS Group Valuation
Is 4GV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4GV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4GV (€0.62) is trading below our estimate of fair value (€1.61)
Significantly Below Fair Value: 4GV is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4GV?
Key metric: As 4GV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 4GV's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | UK£195.14m |
| Market Cap | UK£58.97m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 10.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4GV's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
PHH2 Paul Hartmann | 0.3x | n/a | €713.9m |
PUS PULSION Medical Systems | 3.8x | n/a | €134.4m |
HAEK HAEMATO | 0.3x | n/a | €72.1m |
AAQ1 aap Implantate | 1.8x | n/a | €22.0m |
4GV INSPECS Group | 0.3x | 5.5% | €59.0m |
Price-To-Sales vs Peers: 4GV is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.5x).
Price to Sales Ratio vs Industry
How does 4GV's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: 4GV is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is 4GV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 0.8x |
Price-To-Sales vs Fair Ratio: 4GV is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sensus Healthcare
US$125.2m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$7.25
7D
16.0%
1Y
272.6%
Ship Healthcare Holdings
JP¥196.5b
Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.
5EZ
JP¥12.40
7D
-3.1%
1Y
-4.6%
Shandong Weigao Group Medical Polymer
HK$20.8b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.57
7D
0%
1Y
-36.0%